Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pseudomyxoma Peritonei × Alemtuzumab × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Wilms Tumor 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Pseudomyxoma Peritonei 1 Neuroblastoma 1 Neoplasms, Germ Cell and Embryonal 1 Melanoma 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Kidney Transplantation 1 Digestive System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Burkitt Lymphoma 1 Adenocarcinoma, Clear Cell 1

Interventions

Mitomycin 2 tislelizumab 1 molgramostim 1 cryoprecipitate coagulum 1 Tacrolimus 1 Specimen Handling 1 Sirolimus 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Ipilimumab 1 Hyperthermic Intraperitoneal Chemotherapy 1 Fluorouracil 1 CTLA-4 Antigen 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06084780 2026-01-23

TRANSCAPE

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡